Ionis Pharmaceuticals, Inc. (IONS)
NASDAQ: IONS · Real-Time Price · USD
74.30
+0.13 (0.18%)
Oct 31, 2025, 4:00 PM EST - Market closed
Ionis Pharmaceuticals Revenue
Ionis Pharmaceuticals had revenue of $156.72M in the quarter ending September 30, 2025, with 17.12% growth. This brings the company's revenue in the last twelve months to $966.96M, up 20.41% year-over-year. In the year 2024, Ionis Pharmaceuticals had annual revenue of $705.14M, down -10.48%.
Revenue (ttm)
$966.96M
Revenue Growth
+20.41%
P/S Ratio
12.21
Revenue / Employee
$904,543
Employees
1,069
Market Cap
12.03B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 705.14M | -82.51M | -10.48% |
| Dec 31, 2023 | 787.65M | 200.28M | 34.10% |
| Dec 31, 2022 | 587.37M | -223.09M | -27.53% |
| Dec 31, 2021 | 810.46M | 81.19M | 11.13% |
| Dec 31, 2020 | 729.26M | -393.34M | -35.04% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 435.16B |
| Johnson & Johnson | 92.15B |
| Merck & Co. | 64.24B |
| AbbVie | 59.64B |
| Eli Lilly and Company | 59.42B |
| AstraZeneca | 56.50B |
| Novartis AG | 56.37B |
| Novo Nordisk | 49.11B |
IONS News
- 4 days ago - Ionis Pharmaceuticals, Inc. (IONS) Q3 2025 Earnings Call Transcript - Seeking Alpha
- 5 days ago - Ionis reports third quarter 2025 financial results and highlights progress on key programs - Business Wire
- 7 days ago - Detailed data from the landmark CORE and CORE2 pivotal studies of olezarsen for sHTG to be presented as a late breaker at AHA Scientific Sessions - Business Wire
- 10 days ago - Ionis ranked #2 Top Employer by Science magazine, recognizing industry-leading scientific innovation and company culture - Business Wire
- 12 days ago - Ionis CEO Brett P. Monia receives 2025 Lifetime Achievement Award from the Oligonucleotide Therapeutics Society - Business Wire
- 18 days ago - Ionis to hold third quarter 2025 financial results webcast - Business Wire
- 26 days ago - Ionis Pharmaceuticals, Inc. (IONS) Shareholder/Analyst Call Transcript - Seeking Alpha
- 27 days ago - Ionis showcases transformational medicines and industry-leading pipeline at Innovation Day - Business Wire